Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S - American Depositary Shares
(NQ:
GMAB
)
20.31
+0.22 (+1.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,829,681
Open
20.22
Bid (Size)
20.06 (1)
Ask (Size)
20.52 (1)
Prev. Close
20.09
Today's Range
20.13 - 20.43
52wk Range
19.85 - 32.88
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals.
December 19, 2024
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued.
Via
Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:GMAB.
December 10, 2024
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
Performance
YTD
-36.75%
-36.75%
1 Month
-1.65%
-1.65%
3 Month
-15.87%
-15.87%
6 Month
-21.34%
-21.34%
1 Year
-35.87%
-35.87%
More News
Read More
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
December 09, 2024
From
Genmab A/S
Via
Business Wire
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
November 18, 2024
Via
Chartmill
A Closer Look at 10 Analyst Recommendations For Genmab
November 08, 2024
Via
Benzinga
Preview: Genmab's Earnings
November 05, 2024
Via
Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
October 30, 2024
Via
Chartmill
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
December 08, 2024
From
Genmab A/S
Via
Business Wire
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
December 07, 2024
From
Genmab A/S
Via
Business Wire
Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase.
November 29, 2024
Via
Chartmill
For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals.
November 25, 2024
Via
Chartmill
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Genmab A/S
Via
Business Wire
12 Analysts Have This To Say About Genmab
October 16, 2024
Via
Benzinga
NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
October 09, 2024
Via
Chartmill
NASDAQ:GMAB is an undervalued gem with solid fundamentals.
October 08, 2024
Via
Chartmill
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
October 29, 2024
Via
Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
October 28, 2024
Via
Chartmill
NASDAQ:GMAB, a growth stock which is not overvalued.
October 07, 2024
Via
Chartmill
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 23, 2024
Via
Benzinga
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
September 17, 2024
Via
Chartmill
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
September 16, 2024
Via
Chartmill
Expert Ratings For Genmab
September 09, 2024
Via
Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
September 03, 2024
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
August 26, 2024
Via
Chartmill
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024
From
Genmab A/S
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.